Plasma total homocysteine levels are not associated with medial temporal lobe atrophy, but with white matter changes in alzheimer's disease

Journal of Clinical Neurology (Korea)

Volumn 5, Issue 2, 2009, Pages 85-90

  Kim, Sung Rae ^a   Choi, Seong Hye ^a   Ha, Choong Kun ^a   Park, Shin Goo ^b   Pyun, Hae Wook ^c   Yoon, Dae Hyun ^d  

^a Departments of Neurology   (South Korea)

^b Occupational and Environmental Medicine   (South Korea)

^c Inha University School of Medicine   (South Korea)

^d Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

Author keywords

Aaalzheimer's disease; Atrophy; Homocysteine; Leukoaraiosis; MRI

Indexed keywords

EID: 77954560390     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2009.5.2.85     Document Type: Article

References (39)

1. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077-1080.
2. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999;131:352-355.
3. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 2008;65:642-649.
4. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 2002;51:285-289.
5. Wright CB, Paik MC, Brown TR, Stabler SP, Allen RH, Sacco RL, et al. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke 2005;36:1207-1211.
6. Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. Stroke 1995; 26:1293-1301.
7. Inzitari D. Leukoaraiosis: an independent risk factor for stroke? Stroke 2003;34:2067-2071.
8. Wong T Y, Klein R, Sharrett AR, Couper DJ, Klein BE, Liao D P, et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA 2002;288:67-74.
9. Yamauchi H, Fukuda H, Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis. J Neurol Neurosurg Psychiatry 2002;72:576-582.
10. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986;19:253-262.
11. Jellinger KA, Attems J. Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism. Acta Neurol Scand 2006;114:38-46.
12. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'A-gostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
13. Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F. Homocysteine and Parkinson's disease: a dangerous liaison? J Neurol Sci 2007;257:31-37.
14. Zoccolella S, Simone IL, Lamberti P, Samarelli V, Tortelli R, Serlenga L, et al. Elevated plasma homocysteine levels in patients with amy-otrophic lateral sclerosis. Neurology 2008;70:222-225.
15. Matsui T, Nemoto M, Maruyama M, Yuzuriha T, Yao H, Tanji H, et al. Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimer's disease. Neurodegener Dis 2005;2:299-304.
16. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002;59:787-793.
17. White AR, Huang X, Jobling MF, Barrow CJ, Beyreuther K, Masters CL, et al. Homocysteine potentiates copper- and amyloid beta pep-tide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neu-rochem 2001;76:1509-1520.
18. Scheltens P, Leys D, Barlhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsy-chological correlates. J Neurol Neurosurg Psychiatr 1992;55:967-972.
19. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009;132:195-203.
20. McKhann G., Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
21. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
22. Ueland PM, Refsum H, Stabler S P, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1764-1779.
23. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guideline subcommittee. J Hypertens 1999;17:151-183.
24. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197.
25. National cholesterol education program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994;89:1333-1445.
26. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR AM J Roentgenol 1987;149:351-356.
27. O'Connor DW, Pollitt PA, Treasure FP, Brook CP, Reiss BB. The influence of education, social class and sex on Mini-Mental State scores. Psychol Med 1989;19:771-776.
28. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.
29. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997;28:652-659.
30. Zylberstein DE, Skoog I, Björkelund C, Guo X, Hultén B, Andreasson LA, et al. Homocysteine levels and lacunar brain infarcts in elderly women: the prospective population study of women in Gothenburg. J Am Geriatr Soc 2008;56:1087-1091.
31. Garofolo L, Barros N, Miranda F, D'Almeida V, Cardien LC, Ferreira SR. Association of increased levels of homocysteine and peripheral arterial disease in a Japanese-Brazilian population. Eur J Vasc Endovasc Surg 2007;34:23-28.
32. Hankey GJ, Eikelboom JW. Homocyseine and vascular disease. Lancet 1999;354:407-413.
33. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 2006;103:18727-18732.
34. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Mar-kesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813-817.
35. Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull 1999;55:669-682.
36. den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003;126:170-175.
37. Williams JH, Pereira EA, Budge MM, Bradley KM. Minimal hip-pocampal width relates to plasma homocysteine in community-dwelling older people. Age Ageing 2002;31:440-444.
38. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6926.
39. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 2002;22: 1752-1762.